Contents lists available at ScienceDirect

Taiwanese Journal of Obstetrics & Gynecology

journal homepage: www.tjog-online.com

Original Article

Maternal and fetal outcomes in pregnancies with pulmonary hypertension: Experience of a tertiary center

Zehra Nihal Dolgun*, Cihan Inan, N. Cenk Sayin

Department of Obstetrics and Gynecology, Faculty of Medicine, Edirne, Turkey

A B S T R A C T

Objective: Pregnancies complicated with PHT are serious debates for obstetricians due to high maternal and fetal complication potentials. The aim of the study was to present our maternofetal outcomes in pregnant women with pulmonary hypertension.
Materials and methods: This study was performed using data extracted from the medical files of 23 pregnancies of 18 patients with PHT who were followed-up in the obstetrics and gynecology department.
Results: The average age was 27.09 ± 6.97 (range: 14–38) years. The most frequent maternal cardiac pathologies were cardiac valvular disease (mitral or aortic insufficiency) (n = 4), atrial septal defect (n = 3), mitral stenosis (n = 3), ventricular septal defect (n = 2) and arrhythmia (n = 2). Caesarean section and normal vaginal delivery were performed in 13 and 7 deliveries, respectively. Therapeutic dilatation and curettage was performed in 3 patients. Preterm delivery occurred in 4 pregnancies and there were 2 intrauterine growth retardations, 1 preeclampsia and 2 maternal pulmonary edemas. One patient underwent re-laparotomy 5 days after delivery due to uterine hematoma. Totally, 20 newborns (14 female, 6 male) were delivered. Most of the complications were seen in advanced PHT classes.
Conclusion: The care of the pregnant women with PHT necessitates a well-planned, multidisciplinary approach focusing on close monitoring before, during and after delivery. This approach may contribute to reduction of poor maternal and fetal outcomes.

Introduction

Pulmonary hypertension (PHT), is described classically as a mean pulmonary artery pressure >25 mmHg at rest or 30 mmHg with exercise. It has a poor prognosis and its diagnosis may be either missed or delayed. PHT may be accompanied by various diseases or conditions and brings about a remarkable risk for both the mother and the fetus. Pregnant women with PHT need careful monitoring with close collaboration of a multidisciplinary team. Even though specific treatment modalities are available in the management of PHT during pregnancy, majority of medications are contraindicated due to their teratogenicity [1].

During the course of pregnancy, pulmonary arterial pressure may rise in proportion with the cardiac output with a noteworthy increase in the afterload on the right ventricle and the patients may become symptomatic. Attributed to the deterioration of cardiac function, clinical findings consistent with right heart failure, angina and arrhythmia may occur. Symptoms can exist upon exertion or even at rest with respect to the severity of PHT before pregnancy. Risk for sudden death due to arrhythmia or pulmonary thrombo-embolism is especially increased in these patients [2–5]. High rates of fetal and maternal mortality and intrauterine growth retardations were also reported [6,7]. In these series, the vast majority of deaths occurred during labor, delivery or in the postpartum period as high as 30%–56%, especially in women with idiopathic PHT [7–10]. Since PHT patients have poor tolerance for pregnancy, many authors recommend its avoidance [8,11].

Considering different aspects of mortality and morbidity, the aim of the present study was to share our experience in pregnant women with PHT and to present our maternofetal outcomes to contribute for the establishment of a therapeutic strategy in these patients.

Materials and methods

This retrospective study was performed using the medical records of 23 pregnancies of 18 patients with PHT in the Obstetrics &

* Corresponding author. Department of Obstetrics and Gynecology, Trakya University Faculty of Medicine, Edirne, Turkey. Fax: +902842353451.
E-mail address: dr_nihaldolgun@hotmail.com (Z.N. Dolgun).

Gynecology Department of our tertiary care center between January 2008 and December 2015. The approval of local Institutional Review Board was obtained prior to the study. Since this is a retrospective study, informed consent was not obtained. The study population consisted of Turkish women living in Thrace Region of Turkey.

Parameters involving basic descriptive, medical, cardiac and obstetrical data as well as maternofetal outcomes and complications were collected from the medical files. Standard procedures were followed in close collaboration with departments of pediatrics, cardiology, hematology, chest diseases, neonatology, intensive care unit and anesthesiology. Determination of the gestational age was made according to the last menstrual date and ultrasonography during the first trimester. In case of discrepancy >5 days between these modalities, ultrasonographic data was used. For fetal follow-up, ultrasound Doppler examinations were carried out transabdominally by Voluson ProExpert 730 (General Electric, Connecticut, USA), every two weeks.

Most of our patients had been diagnosed with PHT prior to gestation so they were consulted to cardiology clinic at their first trimester. Pregnancy termination was offered to pregnants who wouldn't tolerate pregnancy by cardiology and obstetrics clinics. According to these suggestions only one patient, New York Heart Association (NYHA) class IV, terminated her two consecutive first trimester gestations after one term vaginal delivery. Other pregnants who were offered termination chose to continue the gestations. Echocardiography was performed and routine cardiopulmonary evaluation was carried out monthly by cardiology department. Patients were informed to be careful about additional cardiac demands and were advised to avoid maneuvers that cause inferior vena cava compression and reduction of venous return to heart due to the cardiorespiratory limitations. As indicated in the relevant literature, patients were advised to admit to the hospital in the second trimester due to the increased likelihood of preterm labor and other complications [12]. All the cases consulted to cardiology clinic at their 3rd trimester and asked about the appropriate route of delivery. The patients who were scheduled for cesarean section had anesthesiology consultation prior to surgery. Monitorization of fetal heart rate was performed twice a week before labor and continuously during labor and all deliveries were performed by a senior attending obstetrician. Since arterial hypoxia can cause vasoconstriction and worsen the hemodynamic outcomes of pregnancy, oxygen was administered in order to keep pulmonary arterial oxygen pressure above 70 mmHg. In this series, anticoagulation and antibiotics were given in 11 patients, eight patients received tocolytic treatment including magnesium sulfate (6 g/20 min loading dose followed by 2 g/hr maintenance therapy), ritodrine hydrochloride (50 mcg/min IV infusion) (which also known to decrease cardiac preload) and nifedipine (30 mg oral loading dose followed by 10 mg/4 h). Anticoagulation is recommended to decrease the risk of venous thromboembolism in patients with restricted cardiopulmonary reserve [13]. In this purpose we started 6000 anti-Xa IU/0.6 ml enoxaparin sodium daily to every patient from the first day of fetal heart beats established. The drug continued during pregnancy and stopped 12 h prior to delivery. After delivery when the bleeding risks were eliminated all our patients were transferred to cardiology clinic for appropriate warfarin treatment.

Pregnant women who had already diagnosed or newly diagnosed as PHT, followed-up and delivered in our clinic included in the study. The ones who were not followed or did not deliver in our center were excluded.

Results

According to the NYHA classification of functional status in PHT five pregnant women were in Class I, three pregnant women were in Class II, five pregnant women were in Class III and five women were Class IV (Table 1). The clinical classifications of patients were also presented on the same table [14].

As shown in Table 1, the average age was 27.09 ± 6.97 (range: 14 to 38) years, in our series. The median gravidity and parity were 2 (range: 1 to 5) and 1 (range: 0 to 4), respectively. Pulmonary hypertension had been diagnosed during pregnancy in 2 cases (11.1%), whereas the vast majority of PHT patients (16/18; 88.8%) had been previously identified. The most frequent maternal cardiac pathologies were cardiac valvular disease (mitral or aortic insufficiency) (n = 4), atrial septal defect (n = 3), mitral stenosis (n = 3), ventricular septal defect (n = 2) and arrhythmia (n = 2). Five patients had undergone mitral valve replacement and three patients had undergone aortic valve replacement prior to their pregnancies. Mean pulmonary arterial systolic pressure was 45.8 ± 16.05 mmHg (range: 30–80). Average duration of pregnancy was $32^{2/7}$ weeks (range: $6^{6/7}$–$40^{3/7}$). There were two twin pregnancies and the remaining was comprised of singleton pregnancies. Chronic renal failure (n = 1), thrombocytopenia (n = 1), thyroiditis (n = 1), preeclampsia (n = 1), nephrotic syndrome (n = 1) and hypothyroidism (n = 1) were the additional morbidities detected in the study group. Echocardiography demonstrated that ejection fraction was greater than 60% in eight patients and grade 2 tricuspid insufficiencies were diagnosed in seven cases. Preterm delivery occurred in four pregnancies and there were two intrauterine growth retardations. Caesarean section (CS) and normal vaginal delivery (NVD) were performed in 13 and 7 deliveries, respectively. Four patients who had previous CS, five patients who had requested tubal ligation, and four patients in preterm labor were terminated via CS. Seven women whose spontaneous contractions started and had an uncomplicated labor, delivered vaginally. In three pregnant women, therapeutic dilatation and curettage was safely carried out due to missed abortion and patients' request. In terms of complications, one patient suffering from excruciating inguinal pain on postoperative day 5, underwent re-laparotomy due to uterine hematoma. Totally, 22 newborns (15 female, 7 male) were delivered and 20 of these are still alive and healthy; whereas the remaining 2 infants were lost to follow-up. The median Apgar score on 1st minute was 9 (range: 3–9), while it was 10 (range: 8–10) on 5th minute. Detailed characteristics of pregnancies according to the NYHA classification of functional status in PHT were showed at Table 2.

Discussion

The current study was carried out to evaluate our maternofetal outcomes in pregnant women with PHT. Our results have shown that an uncomplicated course of pregnancy and favorable clinical results are available in pregnant women with pulmonary hypertension. Thus, we suggest that meticulous care, close follow-up and collaboration of a multidisciplinary team provide satisfactory maternal and fetal outcomes in pregnant women with PHT.

The incidence of pregnancies affected by PHT is 1.1/100,000 women [9]. PHT progressively leads to right ventricular strain and subsequent right heart failure, attributed to the increased pulmonary vascular resistance and right ventricular afterload increase. In case of chronic PHT, hypertrophy of the right ventricle causes increased oxygen consumption, poor contractility and right heart failure [15]. In the relevant literature, despite improvement in survival rates owing to new treatment regimens and utilization of effective multidisciplinary approach, high rates of maternal complications and mortality as high as 56% have been reported because of adverse circulatory and hematological changes that occur in pregnant women with PHT [9,16]. Moreover, fetal risks including prematurity, growth retardation and increased perinatal mortality

Table 1
Descriptive, clinical, obstetric and cardiologic features of 23 pregnancies in 18 patients with pulmonary hypertension.

Variable		
Age (years, mean ± standard deviation, range)		27.09 ± 6.97 (14–38)
Gravidity (median, min–max)		2 (1–5)
Parity (median, min–max)		1 (0–4)
Diagnosis of pulmonary hypertension (n, %)	During pregnancy	2 (11.1)
	Before pregnancy	16 (88.8)
Co-existent cardiac pathologies (n, %)	Valvular disease (mitral or aortic insufficiency)	4 (22.2)
	Atrial septal defect	3 (16.6)
	Mitral stenosis	3 (16.6)
	Ventricular septal defect	2 (11.1)
	Arrhythmia	2 (11.1)
Previous cardiac surgery (n, %)	Mitral valve replacement	5 (27.7)
	Aortic valve replacement	3 (16.6)
Mean pulmonary arterial systolic pressure (mmHg, mean ± standard deviation, range)		45.80 ± 16.05 (30–80)
New York Heart Association (NYHA) Functional Classification in pulmonary hypertension (n, %)	Class I	5 (27.7)
	Class II	3 (16.6)
	Class III	5 (27.7)
	Class IV	5 (27.7)
Average duration of pregnancy (weeks, mean ± standard deviation, range)		$32^{2/7} \pm 4^{4/7}$ ($6^{6/7}$–$40^{3/7}$)
Clinical Classification of Pulmonary Hypertension (Venice 2003) (n, %)	Class 1.1. Idiopathic Pulmonary arterial hypertension	6 (33.3)
	Class 1.3.2. Congenital systemic-to-pulmonary shunts	2 (11.1)
	Class 2.1. Left-sided atrial or ventricular heart disease	2 (11.1)
	Class 2.2. Left-sided valvular heart disease	8 (44.4)
Additional morbidities (n, %)	Chronic renal failure	1 (4.3)
	Thrombocytopenia	1 (4.3)
	Preeclampsia	1 (4.3)
	Thyroiditis	1 (4.3)
	Nephrotic syndrome	1 (4.3)
Perinatal morbidity (n, %)	Preterm delivery	4 (17.3)
	IUGR	2 (8,6)
Mode of delivery or other surgical procedures (n, %)	Caeserean section	13 (59.1)
	Normal vaginal delivery	7 (30.4)
	Dilatation & curettage	3 (13)
	Bilateral tubal ligation	5 (21.7)
Postoperative complications	Uterine hematoma	1 (4.3)
Apgar score (median, min–max)	1st min	9 (3–9)
	5th min	10 (8–10)

IUGR: intrauterine growth retardation.

Table 2
Characteristics of pregnancy histories according to NYHA functional classification of pulmonary hypertension.

	Class I (n = 5)	Class II (n = 3)	Class III (n = 5)	Class IV (n = 5)
NVD	1	2	1	3
C/S	5	0	5	3
D&C	0	1 (due to missed abortion)	0	2 (to terminate pregnancy)
Gestational week at delivery (median, min–max)	37 ($36^{2/7}$–$39^{2/7}$)	$37^{4/7}$, $38^{1/7}$	38 ($28^{5/7}$–40)	36 (32–37)
Birth weight (g) (median, min–max)	2770 (2400–3360)	(3100–3250)	2850 (900–3560)	2670 (1710–2750)
Maternal complication (n)	Postpartum uterine hematoma (n = 1)	0	Pulmonary edema (n = 1)	Pulmonary edema (n = 1)
Perinatal complication (n)	IUGR (n = 2)	0	Preeclampsia (n = 1) Preterm birth (n = 1, twin)	Preterm birth (n = 3)
NICU administration (n)	0	0	3	3

NVD: Normal vaginal delivery, C/S: Cesearean section, D&C: Dilatation and curettage, IUGR: Intra uterine growth retardation, NICU: Neonatal intensive care unit.

are remarkable [5]. Since the maternal and fetal outcomes are poor in pregnant women with PHT, contraception or early termination of pregnancy are encouraged. However, our termination rate was quite low (13%), but still higher than that of a very recent European Registry (4%) upon the women's great demand to continue their pregnancies [10]. As previously suggested [15] patients who insist for continuation of pregnancy must be recruited under meticulous care in a tertiary care center with the supervision of a multidisciplinary team including critical care elements. Like in our series, women who can receive this ideal follow-up standard possibility, maternal–fetal morbidities and mortality may be lower than expected. We have found a preterm delivery rate of 17.3%, and an IUGR rate of 8.6%. Our maternal and fetal outcomes are promising since we came across no mortality in pregnant women or infants during follow-up and Apgar scores were in acceptable limits. Additionally, no adverse events or complications were encountered in the twin pregnancies with PHT. Even preterm delivery and intrauterine growth retardation did not yield any further morbidity in the fetus or the mother. These unexpectedly encouraging findings may be partially linked to the fact that our patients with PHT have a nonsignificant trend towards higher mean pulmonary artery pressure (45.80 ± 16.05 mmHg), so this might explain the lower morbidity rate in our series. Secondly, we strictly followed the women up in close communication and collaboration with other specialists from relevant disciplines including anesthesiology, cardiology, chest diseases, pediatrics and intensive care unit and a

strict follow-up program was adopted. These efforts also might have ensured to obtain the current favorable outcomes.

The ideal delivery mode for pregnant women with PHT is under debate and both normal delivery and CS can be of choice [17,18]. Low forceps delivery can provide lower mortality rate by shortening the second stage of labor in pregnant women with PHT [19]. In active labor, cardiac output increases up to 25% and during maternal pushing efforts to a maximum of 50% those of which might deteriorate the already adverse cardiac function [20]. CS is linked with a high anesthetic risk, but it avoids the prolongation of the second stage of labor and reduces the likelihood of severe vaginal bleeding. Moreover, since peripheral vasodilatation and exacerbation of the already compromised hemodynamic status can lead to serious problems, cautious approach is mandatory for both spinal and general anesthesia. Analgesia, acid-base balance and sedation are other issues those should be taken into account together with efforts that must be spent to avoid myocardial depression or abrupt alterations in blood pressure [1]. In our patients 11 of them had cesarean section and 1 patient had dilatation and curettage (D&C) under general anesthesia without any complications. Two patients had D&C under sedation which also did not complicate with any adverse outcomes.

In our study we found a slight trend through worsening of perinatal and maternal characteristics owing to higher NYHA class of functional status in PHT. The number of pregnancy terminations, pulmonary edema, preeclampsia, preterm birth and NICU administrations were more seen in Class III and IV patients than Class I and II patients. Also class IV implies lower birth weight and gestational weeks at delivery which is relevant with the literature [5] (Table 2). Maternal PHT in twin pregnancies is a more serious condition compared to single ones [21]. In our series, we had two twin pregnancies with PHT classified in Class IV. They were both complicated with preterm birth. Despite close and regular follow-up of these women by cardiologists and obstetricians, they were complicated before 32nd gestational week and their pregnancies had to end in early preterm birth period. The duration of post-partum hospitalization of these women were longer than single pregnancies. We concluded that multiple pregnancies with PHT were more prone to cardiac complications and adverse pregnancy outcomes than single ones.

Anticoagulation should be carefully controlled especially around the time of delivery to minimize risks of operative bleeding and hematoma. Consultation with a hematologist would be useful and a few weeks prior to the delivery a shift from low-molecular-weight heparin to unfractionated heparin can be considered. In the post-partum period, warfarin must be restarted after the post-partum hemorrhage risk has subsided. The duration of this treatment varies with respect to the severity of PHT, but can be extended for a life-long period. In our series, we noted one patient with uterine hematoma who had been receiving low-molecular-weight heparin. In this case, re-laparotomy with drainage of hematoma and surgical control of bleeding was executed. However, we do not suggest the cease of anticoagulant treatment around the time of delivery, because its benefits far outweigh the associated risks. And also in our practice after the risk of postpartum bleeding is subsided, we transfer all our patients to cardiology clinic for appropriate warfarin treatment.

The main limitations of the present study involve small sample size, retrospective design and lack of selection criteria. It must be remembered that stillbirths and infants who died prior to enrollment have not been included in our data and a certain degree of underestimation is likely. These results reflect the experience of a single institution and may not represent the whole population by all means. Social, economic, environmental and ethnic factors may possess a substantial impact on our results. Moreover, selection bias can constitute another remarkable limitation for extrapolation of our results.

In conclusion, pregnant women with PHT still constitute a challenge due to the additional hemodynamic effects of pregnancy on the pre-existing cardiopulmonary problems. Our maternofetal outcomes of pregnant women with PHT are promising with no mortality and no remarkable complications. Proceeding with pregnancy can be advocated in PHT patients who are likely to undergo careful and close monitoring by a multidisciplinary team. Mode of delivery must be decided on an individualized basis. From this point of view, frequent office visits are mandatory to identify any early symptoms and to initiate the appropriate treatment as soon as possible.

Compliance with ethical standards

Ethical approval

Funding

Authors' contributions

ZN Dolgun: Data collection, methodology, investigation, resources, supervision, writing manuscript, formal analysis.

C Inan: Investigation, resources, supervision, writing manuscript, formal analysis.

NC Sayin: Data collection, methodology, supervision, writing manuscript, editing.

Conflicts of interest

There is no conflict of interest by any author.

References

[1] Madden BP. Pulmonary hypertension and pregnancy. Int J Obstet Anesth 2009;18:156−64.
[2] Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 1998;19:1845−55.
[3] Jaigobin C, Silver F. Stroke and pregnancy. Stroke 2000;31:2948−51.
[4] Jaïs X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J 2012;40:881−5.
[5] Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J 2009;30:256−65.
[6] McCaffrey R, Dunn L. Primary pulmonary hypertension in pregnancy. Obstet Gynecol Surv 1964;19:567−91.
[7] Gleicher N, Midwall J, Hochberger D, Jaffin H. Eisenmenger's syndrome and pregnancy. Obstet Gynecol 1979;34:721−41.
[8] Weiss B, Hess OM. Pulmonary vascular disease and pregnancy: current controversies, management strategies and perspectives. Eur Heart J 2000;21: 104−15.
[9] Bassily-Marcus AM, Yuan C, Oropello J, Manasia A, Kohli-Seth R, Benjamin E. Pulmonary hypertension in pregnancy: critical care management. Pulm Med 2012;2012:709407.
[10] Sliwa K, van Hagen IM, Budts W, Swan L, Sinagra G, Caruana M, et al., ROPAC investigators. Pulmonary hypertension and pregnancy outcomes: data from the Registry of pregnancy and cardiac disease (ROPAC) of the European society of cardiology. Eur J Heart Fail 2016;18:1119−28.
[11] Gei A, Montúfar-Rueda C. Pulmonary hypertension and pregnancy: an overview. Clin Obstet Gynecol 2014;57:806−26.

[12] Warnes C. Pregnancy and pulmonary hypertension. Int J Cardiol 2004;97: 11–3.

[13] European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011;32:3147–97.

[14] Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S–12S. 16.

[15] Običan SG, Cleary KL. Pulmonary arterial hypertension in pregnancy. Semin Perinatol 2014;38:289–94.

[16] Weiss B, Zemp L, Seifert B, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: a systemic overview from 1978 through. J Am Coll Cardiol 1998;31:1650–7.

[17] Sharma K, Afshar YR, Bairey-Merz CN, Tapson V, Zakowski M, Kilpatrick SJ. Guidelines and consensus: statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ 2016;6:143.

[18] Sahni S, Palkar AV, Rochelson BL, Kępa W, Talwar A. Pregnancy and pulmonary arterial hypertension: a clinical conundrum. Pregnancy Hypertens 2015;5:157–64.

[19] Vongpatanasin W, Brickner M, Hillis L, Lange RA. The Eisenmenger syndrome in adults. Am Intern Med 1998;128:745–55.

[20] Ouzounian JG, Elkayam U. Physiologic changes during normal pregnancy and delivery. Cardiol Clin 2012;30:317–29.

[21] Badalian SS, Silverman RK, Aubry RH, Longo J. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report. J Reprod Med 2000;45:149–52.